With this understanding, we hypothesized that MPN cells harboring heterozygous BRCA1 mutations exhibit heightened responsiveness to IFNα treatment and that IFNα could potentially enhance the sensitivity of MPN cells with DSB repair gene haploinsufficiency to PARP inhibitors. This evidence concerns the gene BRCA1 and myeloproliferative neoplasm.